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Abstract— Human papillomavirus (HPV) infection is the main 
cause of cervical cancer. Cervical cancer patients go through 
painful long-term treatments and high medical costs. Prevention 
is better than cure. Hence, regular cervical screening is 
recommended for Hong Kong women to prevent this disease. 
Some studies have been conducted in Western countries to show 
that cost-effectiveness can be achieved by combining HPV 
vaccines with regular screening. The study is guided by three 
research groups on the future implication of the cost-effectiveness 
of three cervical cancer prevention strategies: (1) annual Pap 
smear for women aged 25–42, (2) HPV vaccination at age 12, and 
(3) HPV vaccination at age 12 combined with annual Pap smear 
screening at age 25–42. The three groups are compared in terms 
of their total lifetime cost, cost-effectiveness ratio and 
incremental life expectancy. The Markov model software is used 
as the main analytical tool. After analyzing, annual Pap smear 
screening is a cost-effective method to prevent cervical cancer 
that the total lifetime cost was approximately USD145.69; cost-
effectiveness ratio was USD8.80/DALY; and incremental life 
expectancy was 2.72 years. Moreover, HPV vaccination combined 
with annual Pap smear screening is an effective way to prolong 
the life expectancy of women regardless of race that the total 
lifetime cost was approximately USD545.12; cost-effectiveness 
ratio was USD29.56/DALY; and incremental life expectancy was 
2.84 years. Such result provides important insight for the 
formulation of a health care policy to prevent cervical cancer. 
This policy can save lives and reduce local treatment costs. 
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BACKGROUND 
Cervical carcinoma is the second most common cancer 
found in women. Each year, 500,000 new cases of cervical 
cancer are reported, resulting in 250,000 deaths [1]. The World 
Health Organization (WHO) predicted that female mortality all 
over the world would be around 340,000–480,000 in the next 
5–20 years [2]. In Hong Kong, the overall age-standardised 
morbidity and mortality rates of cervical cancer are 9.4 and 2.4 
per 100,000, respectively, according to 2006 figures [3].  
There is evidence that cervical carcinoma develops as a 
result of infection with high-risk genotypes of human 
papillomavirus (HPV). Epidemiological studies show that 70% 
of cervical cancer cases are related to HPV 16 and 18 
infections. Studies also indicate that HPV infection is strongly 
interrelated with sexual activity [4, 5]. Women can be infected 
with HPV during their lifetime. HPV infections can clear 
spontaneously within one year. However, HPV infections can 
develop into cervical intraepithelial neoplasia (CIN) and 
cervical carcinoma when the infections persist and remain 
untreated [6]. 
The prevention of cervical cancer is currently managed in 
Hong Kong through a cervical screening programme launched 
in 2004. Women aged 25 and above are recommended to 
undergo a Pap smear screening every three years [7]. Regular 
cervical screening is an important cervical cancer preventive 
strategy, although the screening alone cannot protect a person 
from acquiring HPV infection. 
The efficient use of resource is a major element in the 
health care system. Decisions on resources distribution, 
efficacy, and safety of new interventions and treatments are of 
utmost importance. However, the costs and cost-effectiveness 
of these new interventions and treatments must be considered. 
Hence, the present study focuses on examining the potential 
effectiveness and cost-effectiveness of prophylactic annual 
cervical screening, HPV vaccination, and HPV vaccination 
combined with annual cervical screening in Hong Kong.  
Clients’ demands are unlimited. Therefore, health policy 
makers should consider how to use health resources in an 
effective and efficient manner. Cost-effective analysis (CEA) 
provides an approach determines the most efficient method of 
utilising limited resources to maximise health benefits. Health 
effects result from the minimisation of resources [8]. The 
WHO Commission on Macroeconomics and Health points out 
that a cost-effectiveness ratio less than three times the gross 
domestic product (GDP) per capita is cost-effective [9]. In 
other words, a health care programme is cost-effective if the 
cost of each disability adjusted life year (DALY), which 
DALYs measure the difference between current health status 
and ideal health status, is either less than three times of the 
GDP per capita. Otherwise, the health care programme is 
identified as not cost-effective. 
PURPOSE, METHODS AND MATERIALS 
The study is guided by three research groups on the future 
implication of the cost-effectiveness of three cervical cancer 
prevention strategies: (1) annual Pap smear for women aged 
25–42, (2) HPV vaccination at age 12, and (3) HPV 
vaccination at age 12 combined with annual Pap smear 
screening at age 25–42. Two research questions guided the 
study: 
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1. What is the future implication of the effectiveness and 
cost-effectiveness of each of the three cervical cancer 
prophylaxis strategies provided to 12-year-old females in Hong 
Kong? 
2. How do the three cervical cancer prophylaxis 
strategies compare with one another in terms of cost-
effectiveness ratio and incremental life expectancy?  
Previous studies have established that 12-year-old girls are 
suitable participants in the CEA of HPV vaccines [11-23]. The 
objective of this study is to determine the effectiveness and 
cost- effectiveness of Hong Kong’s vaccination programme, 
where HPV vaccines are administered to girls aged 12 years in 
addition to the current cervical screening programme. A total 
of 40,853 samples came from the Hong Kong Special 
Administrative Region Government data [10]. A Markov 
model was used to perform the cost-effectiveness analysis in 
the study. The Markov cohort analysis was employed for data 
analysis. The range used for the transition probabilities, costs 
and utilities are shown in Table 2. 
RESULTS 
The total lifetime costs and cost-effectiveness (CE) ratio of 
the three cervical cancer prevention strategies in different 
periods of life among clients were calculated using the 
computer-based Markov model. The calculation was based on 
women assumed to have been infected by HPV 16/18 and have 
natural immunity as well as those assumed to have been 
infected by other high-risk HPV genotypes and have no natural 
immunity. The cost and CE ratio estimation for the three 
strategies were based on the strategies in different periods of 
life and situations. 
Cost of preventive strategies 
The total lifetime costs trended downwards in the three 
strategies following the age of clients. Total lifetime costs 
spent in the annual Pap smear screening only at age 25–42 
were around USD110-190 in different periods of life. Total 
lifetime costs spent in HPV vaccination at age 12 only were 
USD430-450 in different periods of life. Total lifetime costs 
spent in HPV vaccination at age 12 combined with annual Pap 
smear screening at age 25-42 were USD510-590 in different 
periods of life.  
In Tables 1, comparing the result of the total lifetime costs 
in the three strategies, HPV vaccination at age 12 combined 
with annual Pap smear screening at age 25–42 is the most 
expensive strategy in cervical cancer prevention. Annual Pap 
smear screening is the cheapest method for cervical cancer 
prevention. The results show that the costs for HPV 
vaccination only and the annual Pap smear screening were not 
equal to the cost for HPV vaccination combined with annual 
Pap smear screening. This discrepancy can be explained that 
HPV vaccination, annual Pap smear screening, and HPV 
vaccination combined with annual Pap smear screening are not 
substitutes for each other. 
Cost-effectiveness ratio of preventive strategies 
The CE ration trended downwards in the three strategies 
following the age of clients. CE ration decreased from 27 to 1 
USD/DALY in the strategies of annual Pap smear screening 
only at age 25–42. CE ration decreased from 64 to 2 
USD/DALY in the strategies of HPV vaccination at age 12 
only. CE ration decreased from 83 to 3 USD/DALY in the 
strategies of HPV vaccination at age 12 combined with annual 
Pap smear screening at age 25-42. In Tables XX, comparing 
the result of the CE ratio in the three strategies, the ratio of 
HPV vaccination at age 12 combined with annual Pap smear 
screening at age 25–42 was the highest. 
Life expectancy of preventive strategies 
Life expectancy of the three cervical cancer prevention 
strategies increased compared with the life expectancy in no 
intervention. Life expectancy would be increased by 2.715 
years if women had Pap smear screening every year. Life 
expectancy would be increased by 2.767–2.834 years if women 
had HPV vaccination at age 12. The results did not vary, 
whether the client was infected by HPV 16 and 18 or by other 
high-risk HPV genotypes. A very slight difference occurred in 
the cervical cancer prevention strategy of HPV vaccination at 
age 12 combined with annual Pap smear screening at age 25–
42. The incremental life expectancy of this strategy was 2.835 
years if women assumed to have been attacked by HPV 16 and 
18 and have natural immunity received HPV vaccination as 
well Pap smear screening every year. The incremental life 
expectancy of the strategy was 2.832 years if women assumed 
to have been attacked by other high-risk HPV genotypes and 
have no natural immunity received HPV vaccination as well as 
Pap smear screening every year. The difference was merely 
0.003 years. The summary of the results of life expectancy of 
the three cervical cancer prevention strategies is shown in 
Table 1. 
Integrated results 
The integrated results, including average total lifetime 
costs, average cost-effectiveness ratio, and incremental life 
expectancy in each cervical cancer prevention strategy, are 
presented in Table 1. Life expectancy increased in direct 
proportion to total lifetime costs and cost-effectiveness ratio in 
the three cervical cancer prevention strategies. The trend shows 
that the extension of life expectancy is related most to the total 
lifetime costs and the CE ratio used spent in cervical cancer 
prevention. Comparing the three strategies, HPV vaccination at 
age 12 combined with annual Pap smear screening at age 25–
42 can extend life expectancy the most. However, the total 
lifetime cost is naturally the most expensive. Comparing the 
three strategies, annual Pap smear screening only at age 25–42 
is the cheapest method. However, incremental life expectancy 
is the lowest. These results were proven not only in the analysis 
of clients assumed to have been infected by HPV 16 and 18 
and have natural immunity but also in the analysis of clients 
assumed to have been infected by other high-risk HPV 
genotypes and have no natural immunity (Table 1). 
DISCUSSION 
Effectiveness to reduce the risks of cervical cancer 
According to previous studies, the strategy of HPV 
vaccination combined with annual cervical cancer screening 
can reduce a lifetime risk of cervical cancer by 95%–98% [17, 
22, 24-25]. Assuming that HPV vaccines provide protection in 
the community commensurate to the efficacy results from 
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clinical trials, vaccination should be administered in the 
teenage years before girls become sexually active, followed by 
an annual cervical cancer screening. If the sensitivity of Pap 
smear screening drops substantially in a vaccinated population, 
but its specificity remains stable, then Pap smear screening 
may eventually become an attractive option for women of all 
ages. If high levels of vaccine coverage are attained among 
teenage girls, cervical cancer mortality in Hong Kong will 
decrease. If low levels of vaccine coverage are preponderant 
among teenage girls, but mature women who are not infected 
by HPV undergo vaccination and participate in cervical cancer 
screening annually, and there is no change in the specificity of 
Pap smear screening, then cervical cancer mortality in Hong 
Kong will decrease. 
Cost-effectiveness method in cervical cancer prevention 
Focusing on cost and effectiveness, the age-based screening 
programme using annual Pap smear screening as a triage 
method among Hong Kong women has the potential to be more 
cost-effective than HPV vaccination alone, especially for girls 
aged 12, as well as HPV vaccination for girls aged 12 
combined with applying annual Pap smear screening as a triage 
test for women aged 25–42. The total lifetime cost spent was 
USD146, with the target women participating in an annual Pap 
smear screening only at age 25–42 and not vaccinated. It is the 
cheapest cervical cancer preventive strategy compared with the 
others so far. 
The importance of incremental life expectancy by three years 
In current study, it has been found that the life expectancy 
would be increased around three years through the prevention 
strategy of HPV vaccination combined with annual Pap smear 
screening. Although the increase in life expectancy is three 
years, it is very important for the society because of four 
reasons. First, show a positive relationship between life 
expectancy and GDP. The increment of life expectancy affects 
GDP in a positive way because the productivity of the society 
will rise no matter population is in a good or bad health state. 
Palpably, productivity of individuals will increase if they have 
healthy life expectancy. Although individuals have unhealthy 
life expectancy, productivity of the society will also increase. It 
is because patients need drugs, treatments, nursing care and 
other allied health services. In the view of production, 
individuals produce more medical goods due to disease. 
Therefore, health has a first-order impact on economic growth 
[26]. Second, lift expectancy is an objective factor to present a 
subjective well-being. In Papavlassopulos & Keppler study 
[27], it pointed that life extension reflects an improvement of 
well-being, although subjective well-being can differ from 
person to person or culture to culture. Healthcare has as much 
impact on life expectancy as income. The appropriate income 
cost for access to healthcare if life expectancy is to increase. In 
addition, a market oriented healthcare system can deteriorate 
inequities in life expectancy as well as well-being. Third, to 
measure the effectiveness of medical interventions, the gain in 
life expectancy is a main element. Refer to the result of 
incremental life expectancy; physicians decide whether the 
benefits of an intervention outweigh its harm or the insurance 
companies consider whether or not cover a new medical 
intervention. The result also helps a pharmaceutical company 
concern whether a new drug is more effective than the standard 
drugs to be worth marketing. The most important is it helps the 
healthcare professionals or policy makers designing guidelines 
for clinical practice [28]. Last but not least, it is a global 
indicator to disclose whether changes are valuable for 
improving both physical and psychological health states of the 
population, for allocating resources, and for political 
programmes measurement [29]. 
Limitations 
This study has several important limitations. First, the 
researcher could not model the natural history of multiple 
HPV infections. Therefore, vaccination against HPV 16 and 
18 in this study was counted to reduce the total number of 
HPV infections. However, morbidity of cervical cancer caused 
by other high-risk HPV genotypes increased marginally 
because women are still at risk of acquiring other HPV types, 
whether or not they received HPV vaccination. Explaining the 
natural history of multiple infections and the effect of natural 
history of high-risk HPV genotypes when vaccine targets are 
eliminated is important [34]. Second, potential cross-
protection from other high-risk HPV genotypes was not 
considered [34]. Third, herd immunity was not considered that 
the effect might be underestimated [30-32, 34]. Fourth, data 
depended on the preferences of clients and parents, likelihood 
of vaccine acceptability, and behavioural response (i.e., annual 
cervical cancer screening) to an intervention only partially 
effective against cervical cancer [17, 33-34]. Finally, the main 
uncertainties include the nature and duration of natural and 
vaccine-induced immunity against HPV, the effect of vaccine-
induced immunity on mature women, the nature of the 
interactions between different types of HPV, the decline of the 
prevalence of HPV 16 and 18, and the presence of cross-
protection in other high-risk HPV genotypes by the current 
HPV vaccination [6, 25, 35]. 
CONCLUSION 
This study was conducted to assess the future implications of 
the cost-effectiveness of three cervical cancer prophylaxis 
strategies, namely, annual Pap smear screening only at age 
25–42, HPV vaccination at age 12 only, and HPV vaccination 
at age 12 combined with annual Pap smear screening at age 
25–42 provided to teenage girls in Hong Kong. Furthermore, it 
aims to help ascertain the most effective and cost-effective 
methods in cervical cancer prevention as well determine the 
best method to prolong life expectancy by comparing the 
strategies. It has been found that HPV vaccination can 
effectively stop HPV infection transmitted to CIN but cannot 
prevent all HPV genotypes. Cervical screening is the most 
cost-effective method in cervical cancer prevention, but it 
cannot stop the progress of CIN development. In the 
achievement of the goal of 100% reduction of cervical cancer, 
the frequency of cervical cancer screening after vaccination is 
the more important determinant for the clinical and economic 
outcomes of an HPV vaccination programme compared with 
screening only. Therefore, with the main aim of avoiding 
cervical cancer, an HPV vaccination programme using the 
currently available vaccines should only be considered if 
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annual cervical cancer screening after vaccination can be 
maintained. The researcher attempted to offer methods of 
prolonging life expectancy by providing qualitative insight to 
policymakers regarding the consequences of utilizing the 
current cervical cancer screening strategy and HPV 
vaccination for cervical cancer prevention. This study showed 
prevention is much more cost-effective than medical 
treatment. That will make our scarce resource more cost-
effective, and then produce better health for women, making a 
happy life for girls. 
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Table 1 Total lifetime costs, cost-effectiveness ratio, and incremental life expectancy in the three cervical cancer prevention strategies 
 Women attacked by HPV 16 and 18 and having natural immunity Women attacked by other high-risk HPV genotypes and not 
having related natural immunity 
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Table 2 Probabilities, costs and utilities used in the model 
Model variables: probabilities and ranges used in sensitivity analysis 
Variables  Median Range Source 
Normal to CIN 1  0.0211 0.0004–0.0418 [36] 
CIN 1 to CIN 2, 3  0.00525 0.0007–0.0098 [36] 
CIN 2, 3 to local invasive cancer  0.0050  0.0020–0.0080 [36] 
Regression of CIN 1  0.0145 0.0034–0.0256 [36] 
Regression of CIN 2, 3  0.00365 0.0015–0.0058 [36] 
Progression of invasive cancer stage     
Local to regional  0.0250  0.0100–0.0400 [36] 
Regional to distant  0.0375 0.0250–0.0500 [36] 
5-year cervical cancer survival rate     
Local   0.865 0.80–0.93 [36] 
Regional   0.47 0.28–0.66 [36] 
Distant  0.185 0.04–0.33 [36] 
Annual probability of symptom detection     
Local   0.38 0.10–0.66 [36] 
Regional   0.60  0.36–0.84 [36] 
Distant  0.835  0.68–0.99 [36] 
Test characteristics     
Sensitivity of conventional cervical cytology  0.75 0.5–1.0 [36] 
Specificity of conventional cervical cytology  0.95 0.9–1.0 [36] 
Reduction in HPV incidence and conditional (caused by HPV 16, 18) on immune response after having 
HPV vaccination 
 1 N/A 
[36] 
Probability of diagnosing the disease and treating it well  1 N/A [36] 
Cost data for the study (USD) 
Cost of three doses of HPV vaccines#  402 N/A [41] 
Direct medical cost*     
Conventional cervical cytology  115 40-190 [36-39] 
Test cost  55 10-100 [36-39] 
Office visit  13.5 7-20 [36-39] 
Time cost  33.5 17-50 [36-39] 
Travel cost  13 6-20 [36-39] 
Aggregate cost*     
Colposcopy and biopsy  275 150-400 [36-39] 
CIN 1  350 200-500 [36-39] 
CIN 2, 3  700 500-900 [36-39] 
Local invasive cancer  15,750 9,500-22,000 [36-39] 
Regional invasive cancer  20,350 11,700-29,000 [36-39] 
Distant invasive cancer     47,085 12,670-81,500 [36-39] 
Note: * Cost data were Hong Kong data in 2000 [36-39] and were the base cases considered as the market prices. These data were adjusted by the rate of inflation 
and deflation from 2001 to 2009 that inflation and deflation were taken from the Census and Statistics Department, HKSAR; and with 3% annual discount, which 
it was recommended by WHO-CHOICE [40], from 2010 to 2036. # Data came from a US study [41].   
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